Farwa Basit

Farwa Basit

Auto-generated profile, based on publicly available information

Farwa Basit

Osteoimmunology & Drug Discovery Research Group, Department of Biology, College of Science, Mathematics and Technology, Wenzhou-Kean University, 88 Daxue Road, Wenzhou 325060, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2024 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
FBFarwa Basit
Farwa Basit
MKMuhammad Khalid
Muhammad Khalid
Ali El-KeblawyAli El-Keblawy
Ali El-Keblawy
MSMohamed Sheteiwy
Mohamed Sheteiwy
SSSaad Sulieman
Saad Sulieman
Faisal ZulfiqarFaisal Zulfiqar
Faisal Zulfiqar

Verified
Journal Article
Open access
PDF file
LZLifang Zhang
Lifang Zhang
CXChengxu Xie
Chengxu Xie
XBXinyi Bao
Xinyi Bao
XLXiaohan Li
Xiaohan Li
HVHeriberto Velez
Heriberto Velez
Vishwa DeepakVishwa Deepak
Vishwa Deepak
Excessive osteoclast formation is a key contributor to pathological bone loss in disorders such as osteoporosis and rheumatoid arthritis. Asarinin, a natural lignan, has not previously been examined in the context of osteoclast differentiation. Here, we investigated the anti-osteoclastogenic effects of asarinin using RANKL-stimulated RAW264.7 cells. Asarinin significantly suppressed TRAP-positive multinucleated osteoclast formation. Mechanistically, asarinin selectively inhibited RANKL-induced phosphorylation of p38 and ERK MAPKs, leading to reduced c-Fos expression and inhibition of NFATc1 activation. In addition, asarinin disrupted actin ring formation in mature osteoclasts. Collectively, these findings identify asarinin as a pathway-selective inhibitor of osteoclast differentiation, acting through a mechanism consistent with modulation of the p38/ERK–c-Fos–NFATc1 signaling cascade while sparing parallel signaling pathways.